Barclays’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-25,000
| Closed | -$170K | – | 5333 |
|
|
2026
Q1 | $170K | Hold |
25,000
| – | – | ﹤0.01% | 3782 |
|
|
2025
Q4 | $211K | Buy |
25,000
+6,250
| +33% | +$69.1K | ﹤0.01% | 4284 |
|
|
2025
Q3 | $243K | Buy |
18,750
+9,375
| +100% | +$110K | ﹤0.01% | 4207 |
|
|
2025
Q2 | $91.5K | Buy |
+9,375
| New | +$98.9K | ﹤0.01% | 4599 |
|
|
2025
Q1 | – | Sell |
-1
| Closed | -$13 | – | 5236 |
|
|
2024
Q4 | $13 | Sell |
1
-2
| -67% | -$38 | ﹤0.01% | 5223 |
|
|
2024
Q3 | $73 | Sell |
3
-22
| -88% | -$492 | ﹤0.01% | 5195 |
|
|
2024
Q2 | $479 | Sell |
25
-2,331
| -99% | -$62.5K | ﹤0.01% | 4709 |
|
|
2024
Q1 | $88.6K | Sell |
2,356
-256
| -10% | -$10.6K | ﹤0.01% | 4474 |
|
|
2023
Q4 | $79K | Buy |
2,612
+2,270
| +664% | +$49.5K | ﹤0.01% | 4690 |
|
|
2023
Q3 | $7.49K | Sell |
342
-14,043
| -98% | -$496K | ﹤0.01% | 4342 |
|
|
2023
Q2 | $559K | Buy |
14,385
+13,239
| +1,155% | +$1.17M | ﹤0.01% | 2681 |
|
|
2023
Q1 | $106K | Sell |
1,146
-5,020
| -81% | -$630K | ﹤0.01% | 4143 |
|
|
2022
Q4 | $882K | Buy |
6,166
+1,016
| +20% | +$254K | ﹤0.01% | 2907 |
|
|
2022
Q3 | $1.17M | Buy |
5,150
+5,061
| +5,687% | +$1.28M | ﹤0.01% | 2118 |
|
|
2022
Q2 | $21K | Sell |
89
-173
| -66% | -$38K | ﹤0.01% | 4369 |
|
|
2022
Q1 | $84K | Buy |
+262
| New | +$60.3K | ﹤0.01% | 3859 |
|
|
2020
Q3 | – | Sell |
-37
| Closed | -$9K | – | 5165 |
|
|
2020
Q2 | $9K | Sell |
37
-8
| -18% | -$1.57K | ﹤0.01% | 5331 |
|
|
2020
Q1 | $5K | Sell |
45
-94
| -68% | -$14K | ﹤0.01% | 5926 |
|
|
2019
Q4 | $23K | Buy |
139
+62
| +81% | +$31.4K | ﹤0.01% | 5945 |
|
|
2019
Q3 | $76K | Sell |
77
-11
| -13% | -$12.3K | ﹤0.01% | 5674 |
|
|
2019
Q2 | $101K | Buy |
88
+60
| +214% | +$54.4K | ﹤0.01% | 5685 |
|
|
2019
Q1 | $21K | Buy |
28
+22
| +367% | +$20K | ﹤0.01% | 6337 |
|
|
2018
Q4 | $6K | Sell |
6
-30
| -83% | -$39.5K | ﹤0.01% | 6360 |
|
|
2018
Q3 | $61K | Sell |
36
-8
| -18% | -$10.4K | ﹤0.01% | 5945 |
|
|
2018
Q2 | $45K | Buy |
44
+32
| +267% | +$34.5K | ﹤0.01% | 5694 |
|
|
2018
Q1 | $13K | Buy |
+12
| New | +$22K | ﹤0.01% | 6571 |
|
Other funds holding ACET
RCM
O
SCM
SSA
Barclays's ACET Position: Q2 2026 in Review
Barclays sold out of Adicet Bio (ACET) in Q2 2026, closing a stake of 25,000 shares — an estimated $170K sold.
Barclays first reported a position in ACET in Q1 2018 and held it in 26 quarters. The position peaked at $1.17M in Q3 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.
- Barclays reported no remaining Adicet Bio position as of Q2 2026 after selling out during the quarter.
- Barclays sold 25,000 Adicet Bio shares in Q2 2026, an estimated $170K.
- Barclays first reported a position in Adicet Bio in Q1 2018 and held it in 26 quarters.
- Barclays's Adicet Bio position peaked at $1.17M in Q3 2022.
- 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.